Brendon Neuen, MBBS, PhD, joins hosts to discuss the landmark FLOW trial and its implications on the future of chronic kidney disease management as well as other compelling data surrounding semaglutide from the 61st European Renal Association Congress.

Key Highlights:
00:00 - Intro
01:12 - ERA Recap 
03:06 - FLOW Background
05:20 - FLOW Results
06:56 - FLOW Reaction (Neuen)
09:13 - Semaglutide Mortality Benefit
12:43 - Semaglutide 2.4 in CKD
17:30 - Implementation Science
22:30 - Management Approach

In this episode of Don’t Miss a Beat, Javed Butler, MD, joins hosts Muthiah Vaduganthan, MD, MPH, and Steve Greene, MD, for a breakdown of the EMPACT-MI trial, including primary results, secondary findings, how data from DAPA-MI and EMPACT-MI complement each other, and what is next for the SGLT2 inhibitor class. 

Key Highlights:

00:00 - Intro
01:57 - Trial Design and Results
07:00 - Inclusion Criteria and Patient Characteristics
10:53 - Primary Results of EMPACT-MI
14:34 - Subgroup Analyses
15:27 - Implications for Post-MI Patient Population 
19:53 - Takehome Messages for Care
23:39 - Kidney Outcomes in Post-MI Patient Population

In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts give an overview of the DAPA-MI trial. 

On the floor from HFSA 2023!
Hosts Muthiah Vaduganathan, MD, MPH, and Steve Greene, MD, are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction

In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

Hosts are joined by Tor Biering-Sørenson, MD, MSc, MPH, PhD, to discuss the NUDGE FLU trial and how the lessons learned can inform implementation strategies for various other types of therapies.

Don't Miss a Beat hosts are joined by Alexandre Mebazaa, MD, PhD, lead investigator of the STRONG-HF trial, to discuss the inspiration for the trial, its design, and important takeaways for those looking to implement a similar strategy of rapid, in-hospital uptitration of GDMT in heart failure at their own practice.

Video Version

Muthiah Vaduganathan, MD, MPH, of Brigham and Women’s Hospital, and Stephen Greene, MD, of the Duke University School of Medicine, are bringing you insights from the floor at the American Heart Association 2022 Scientific Sessions in Chicago, Il. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.